Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,946.93 -122.75 (-0.31%) Hang Seng
19,220.62 -415.60 (-2.12%) FTSE 100
8,416.45 -7.75 (-0.09%) Bitcoin USD
69,700.21 +1,200.95 (+1.75%) CMC Crypto 200
1,518.77 +30.22 (+2.03%)
Genmab A/S (GMAB)
| Previous close | 29.69 |
| Open | 29.44 |
| Bid | 29.26 x 100 |
| Ask | 29.33 x 100 |
| Day's range | 29.21 - 29.44 |
| 52-week range | 26.32 - 42.72 |
| Volume | |
| Avg. volume | 526,164 |
| Market cap | 18.957B |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | 24.21 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Genmab Completes Acquisition of ProfoundBio
COPENHAGEN, Denmark, May 21, 2024--Genmab A/S (Nasdaq: GMAB) announced today that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers in an all-cash transaction of USD 1.8 billion (subject to adjustment for ProfoundBio’s closing net debt and transaction expenses).
- GlobeNewswire
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; May 21, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from May 13, 2024 to May 17, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement
- Business Wire
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
COPENHAGEN, Denmark, May 14, 2024--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2024 European Hematology Association (EHA) Congress, being held in Madrid, Spain and virtually, June 13-16, 2024.
